Literature DB >> 21172875

Adaptive clinical trials: the promise and the caution.

Donald A Berry.   

Abstract

Mesh：

Year:  2010        PMID： 21172875     DOI： 10.1200/JCO.2010.32.2685

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  59 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

Authors:  Lorenzo Trippa; Eudocia Q Lee; Patrick Y Wen; Tracy T Batchelor; Timothy Cloughesy; Giovanni Parmigiani; Brian M Alexander
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

3.  Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.

Authors:  Timothy C Guetterman; Michael D Fetters; Laurie J Legocki; Samkeliso Mawocha; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Res Regul Aff       Date:  2015-09-18

Review 4.  Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Authors:  Brian M Alexander; Patrick Y Wen; Lorenzo Trippa; David A Reardon; Wai-Kwan Alfred Yung; Giovanni Parmigiani; Donald A Berry
Journal:  Neuro Oncol       Date:  2013-07-14       Impact factor: 12.300

5.  Achieving integration in mixed methods designs-principles and practices.

Authors:  Michael D Fetters; Leslie A Curry; John W Creswell
Journal:  Health Serv Res       Date:  2013-10-23       Impact factor: 3.402

6.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

7.  Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Authors:  Lorenzo Trippa; Patrick Y Wen; Giovanni Parmigiani; Donald A Berry; Brian M Alexander
Journal:  Neuro Oncol       Date:  2015-01-07       Impact factor: 12.300

8.  Bayesian Adaptive Design Scope of Utilizing it for Research in Palliative Care.

Authors:  Abhijit Nair; Praneeth Suvvari; Srinivas Shyam Prasad Mantha; Basanth Kumar Rayani
Journal:  Indian J Palliat Care       Date:  2021-02-17

Review 9.  The intensive care medicine research agenda for airways, invasive and noninvasive mechanical ventilation.

Authors:  Samir Jaber; Giacomo Bellani; Lluis Blanch; Alexandre Demoule; Andrés Esteban; Luciano Gattinoni; Claude Guérin; Nicholas Hill; John G Laffey; Salvatore Maurizio Maggiore; Jordi Mancebo; Paul H Mayo; Jarrod M Mosier; Paolo Navalesi; Michael Quintel; Jean Louis Vincent; John J Marini
Journal:  Intensive Care Med       Date:  2017-08-07       Impact factor: 17.440

10.  Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.

Authors:  Lillian L Siu; S Percy Ivy; Erica L Dixon; Amy E Gravell; Steven A Reeves; Gary L Rosner
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.